STARTech Early Ventures

SensorLogic is a provider of cloud-based machine-to-machine (M2M) application hosting services, specializing in platform-as-a-service (PaaS) solutions. The company offers a comprehensive service delivery platform that includes open device and network management, business logic, and application services. This enables organizations to create and deploy customizable M2M applications that leverage connected devices. Through its XpressIQ Service Suite, SensorLogic provides customers with ready-to-use applications for GPS tracking, asset monitoring, and control, along with value-added network services. The platform is designed to facilitate the seamless integration of M2M technologies, allowing businesses to enhance operational efficiency and improve service delivery.

SensorLogic is a provider of cloud-based machine-to-machine (M2M) application hosting services, specializing in platform-as-a-service (PaaS) solutions. The company offers a comprehensive service delivery platform that includes open device and network management, business logic, and application services. This enables organizations to create and deploy customizable M2M applications that leverage connected devices. Through its XpressIQ Service Suite, SensorLogic provides customers with ready-to-use applications for GPS tracking, asset monitoring, and control, along with value-added network services. The platform is designed to facilitate the seamless integration of M2M technologies, allowing businesses to enhance operational efficiency and improve service delivery.

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company that develops innovative therapeutics aimed at treating serious and life-threatening diseases by targeting molecular pathways involved in cellular metabolism and inflammation. The company is advancing several clinical trial programs, including bardoxolone methyl for chronic kidney disease related to Alport syndrome and pulmonary arterial hypertension, as well as omaveloxolone for Friedreich’s ataxia. Additionally, Reata is conducting studies for various forms of chronic kidney disease, including IgA nephropathy and diabetic kidney disease. The company is also developing RTA 901 for neurological conditions such as diabetic neuropathy and exploring RORgT inhibitors in preclinical stages for autoimmune and fibrotic diseases. Reata has strategic collaborations with Kyowa Kirin to develop bardoxolone in several Asian markets and with AbbVie to research second-generation Nrf2 activators for various indications. Founded in 2002 and headquartered in Plano, Texas, Reata Pharmaceuticals was previously known as Reata Discovery, Inc. until its name change in 2005.

Mirage Networks was a network security company focused on providing effective and easily manageable security solutions for enterprises. The company specialized in network-access technology and developed a comprehensive network access control platform. This platform allowed users to manage network access across various devices, endpoints, and operating systems. Mirage Networks operated through a global network of resellers, original equipment manufacturers, and managed security service providers, ensuring widespread availability of its solutions.

Quickshift provides warehousing and e-commerce fulfillment services along with fleet support for distribution. It helps streamline the storage, distribution, and fulfillment across retail, wholesale, and e-commerce channels. The company was founded in 2014 and is headquartered in Pune, Maharashtra, India.

Pintail Technologies, Inc. specializes in real-time adaptive test technology for the semiconductor manufacturing sector. The company provides SwifTest, an online adaptive test module that integrates with automated test equipment (ATE) to capture and analyze data in real time. Additionally, Pintail offers TestScape, a database system designed to manage this data effectively. Among its solutions are TestScape-Charzilla for device characterization, TestScape-Aware for centralized test result dashboards, and TestScape-OPS for managing test floor operations and enhancing overall equipment effectiveness (OEE). The company also delivers TestVision for test data analysis, SwifTest-TTO for real-time statistical sampling to reduce test times, and SwifTest-MAX, which allows for complex monitoring and analysis. Pintail Technologies serves a diverse clientele, including integrated device manufacturers and automated test equipment companies, with a presence in markets across the United States, Asia, and Europe. The company has established strategic alliances with industry leaders such as Teradyne and Salland Engineering to enhance its offerings.

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company that develops innovative therapeutics aimed at treating serious and life-threatening diseases by targeting molecular pathways involved in cellular metabolism and inflammation. The company is advancing several clinical trial programs, including bardoxolone methyl for chronic kidney disease related to Alport syndrome and pulmonary arterial hypertension, as well as omaveloxolone for Friedreich’s ataxia. Additionally, Reata is conducting studies for various forms of chronic kidney disease, including IgA nephropathy and diabetic kidney disease. The company is also developing RTA 901 for neurological conditions such as diabetic neuropathy and exploring RORgT inhibitors in preclinical stages for autoimmune and fibrotic diseases. Reata has strategic collaborations with Kyowa Kirin to develop bardoxolone in several Asian markets and with AbbVie to research second-generation Nrf2 activators for various indications. Founded in 2002 and headquartered in Plano, Texas, Reata Pharmaceuticals was previously known as Reata Discovery, Inc. until its name change in 2005.

Voyence provides configuration and change management solutions that automate critical change, compliance, and activation processes. The company offers VoyenceControl NG solution, which manages various devices in a heterogeneous infrastructure; automates configuration management lifecycle, including design, change, and compliance; and collects data in its repository, including configuration, asset/hardware, and change and audit information. It offers compliance/security, change/configuration, and extending network management solutions. The company's customers include financial, healthcare, education, government, manufacturing, services, technology, and transportation organizations. Voyence, Inc. was founded in 2000 as PowerUp Networks and it changed its name to Voyence, Inc. in 2003. The company is headquartered in Richardson, Texas.

Metreos was founded in 2001 by [Louis Marascio](http://www.crunchbase.com/person/louis-marascio) and [Mark Richards](http://www.crunchbase.com/person/mark-richards) to provide an IP telephony development and run-time platform to help companies build, deploy, and manage IP telephony applications. Metreos provided both packaged applications and a set of tools for designing, developing, deploying, and managing applications deployed on IP telephony networks. Their primary customer base were large enterprises who had invested significant capital in replacing aging [TDM](http://en.wikipedia.org/wiki/Time-division_multiplexing) based phone systems with new [Voice-over-IP](http://en.wikipedia.org/wiki/Voice_over_IP) phone systems, specifically those who had chosen Cisco Systems as their VoIP vendor of choice. Large Cisco customers began to use the Metreos product suite in 2004 with early deployments by Lehman Brothers and BearingPoint. Frustrated by the lack of support from their primary IP PBX vendor, Metreos customers were able to use the Metreos Communications Environment to customize their IP telephony deployment to their liking, often times implementing features that were lost in the transition from TDM to IP. Recognizing that many of their large marque customers were using the Metreos product to enhance their Cisco deployment, Cisco purchased Metreos in June 2006 for $28 million USD.

AppTrigger, Inc. provides telecommunications application connectivity solutions. It offers Application Session Controller software, a network element that sits between the application cloud and the converging network/control layer to provide and manage connectivity to the evolving network for multiple applications. The company also provides support programs, and professional and training services. AppTrigger, Inc. was formerly known as Carrius Technologies, Inc. The company was founded in 2002 and is based in Richardson, Texas.

Metreos was founded in 2001 by [Louis Marascio](http://www.crunchbase.com/person/louis-marascio) and [Mark Richards](http://www.crunchbase.com/person/mark-richards) to provide an IP telephony development and run-time platform to help companies build, deploy, and manage IP telephony applications. Metreos provided both packaged applications and a set of tools for designing, developing, deploying, and managing applications deployed on IP telephony networks. Their primary customer base were large enterprises who had invested significant capital in replacing aging [TDM](http://en.wikipedia.org/wiki/Time-division_multiplexing) based phone systems with new [Voice-over-IP](http://en.wikipedia.org/wiki/Voice_over_IP) phone systems, specifically those who had chosen Cisco Systems as their VoIP vendor of choice. Large Cisco customers began to use the Metreos product suite in 2004 with early deployments by Lehman Brothers and BearingPoint. Frustrated by the lack of support from their primary IP PBX vendor, Metreos customers were able to use the Metreos Communications Environment to customize their IP telephony deployment to their liking, often times implementing features that were lost in the transition from TDM to IP. Recognizing that many of their large marque customers were using the Metreos product to enhance their Cisco deployment, Cisco purchased Metreos in June 2006 for $28 million USD.

AppTrigger, Inc. provides telecommunications application connectivity solutions. It offers Application Session Controller software, a network element that sits between the application cloud and the converging network/control layer to provide and manage connectivity to the evolving network for multiple applications. The company also provides support programs, and professional and training services. AppTrigger, Inc. was formerly known as Carrius Technologies, Inc. The company was founded in 2002 and is based in Richardson, Texas.

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company that develops innovative therapeutics aimed at treating serious and life-threatening diseases by targeting molecular pathways involved in cellular metabolism and inflammation. The company is advancing several clinical trial programs, including bardoxolone methyl for chronic kidney disease related to Alport syndrome and pulmonary arterial hypertension, as well as omaveloxolone for Friedreich’s ataxia. Additionally, Reata is conducting studies for various forms of chronic kidney disease, including IgA nephropathy and diabetic kidney disease. The company is also developing RTA 901 for neurological conditions such as diabetic neuropathy and exploring RORgT inhibitors in preclinical stages for autoimmune and fibrotic diseases. Reata has strategic collaborations with Kyowa Kirin to develop bardoxolone in several Asian markets and with AbbVie to research second-generation Nrf2 activators for various indications. Founded in 2002 and headquartered in Plano, Texas, Reata Pharmaceuticals was previously known as Reata Discovery, Inc. until its name change in 2005.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, that specializes in the discovery and development of antibody-based therapeutics for cancer treatment. The company's portfolio includes several investigational products, such as Margetuximab, a monoclonal antibody in Phase III trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other candidates in development include MGA012 and MGD013, both targeting PD-1, as well as MGD019, which targets multiple immune checkpoints. MacroGenics is also advancing MGC018, an antibody-drug conjugate targeting B7-H3, and MGD014, a DART molecule designed for HIV-infected cells. The company has formed strategic collaborations with several organizations to enhance its research and development efforts. Founded in 2000, MacroGenics is committed to innovating immunotherapeutics for cancer and other related diseases.

OraMetrix, Inc. provides 3-D technology solutions for facilitating and improving the quality of orthodontic care. It offers an orthodontic treatment system that allows the use of precision digital tools throughout the diagnosis, treatment planning and monitoring, and arch wire customization processes of the orthodontic treatment. OraMetrix, Inc. was formerly known as Orthotel, Inc. The company was founded in 1998 and is based in Richardson, Texas with an additional office in Berlin, Germany.